Exhibit 99.1
25 September 2017
Motif Bio plc
(“Motif” or the “Group”)
Holding(s) in the Company
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it was informed on 22 September 2017 by Amphion Innovations plc (“Amphion”) that a total of 4,390,000 ordinary shares in the Company had been sold in respect of a partial repayment of a loan facility, which is secured by Motif Bio shares held by Amphion. Amphion is now the beneficial owner of 37,150,645 ordinary shares in the Company, representing 14.1% of the issued share capital.
Following this sale, Amphion has agreed an amendment to the loan facility with its lender such that no further Motif Bio shares will be sold before 15 January 2018. The full details of this amendment may be found in the RNS announcement released by Amphion today.
The TR-1 disclosure is set out below.
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached(ii): | | Motif Bio plc |
| | |
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) |
| | |
Non-UK issuer | | o |
| | |
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) |
| | |
An acquisition or disposal of voting rights | | x |
An acquisition or disposal of financial instruments | | o |
An event changing the breakdown of voting rights | | o |
Other (please specify)(iii): | | o |
| | |
3. Details of person subject to the notification obligation(iv) | | |
| | |
Name | | Amphion Innovations plc |
City and country of registered office (if applicable) | | |
| | |
4. Full name of shareholder(s) (if different from 3.)(v) | | |
| | |
Name | | |
City and country of registered office (if applicable) | | |
| | |
5. Date on which the threshold was crossed or reached(vi): | | September 22 2017 |
| | |
6. Date on which issuer notified (DD/MM/YYYY): | | September 22 2017 |
| | |
7. Total positions of person(s) subject to the notification obligation |
| | % of voting rights
attached to shares
(total of 8. A) | | % of voting rights
through financial
instruments
(total of 8.B 1 + 8.B 2) | | Total of both in %
(8.A + 8.B) | | Total number of
voting rights of
issuer(vii) | |
Resulting situation on the date on which threshold was crossed or reached | | 14.1% | | | | | | 263,128,775 | |
Position of previous notification (if applicable) | | 15.8% | | | | | | | |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached(viii)
A: Voting rights attached to shares
| | Number of voting rights(ix) | | % of voting rights | |
| | | | | | | | | |
Class/type of
shares ISIN code (if possible) | | Direct
(Art 9 of Directive
2004/109/EC) (DTR5.1) | | Indirect
(Art 10 of Directive 2004/109/EC)
(DTR5.2.1) | | Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1) | | Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1) | |
GB008BVVT4H71 | | 37,150,645 | | | | 14.1% | | | |
| | | | | | | | | |
SUBTOTAL 8. A | | 37,150,645 | | 14.1% | |
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial
instrument | | Expiration
date(x) | | Exercise/
Conversion Period(xi) | | Number of voting rights
that may be acquired if
the instrument is
exercised/converted. | | % of voting rights |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | SUBTOTAL 8. B 1 | | | | |
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial
instrument | | Expiration
date(x) | | Exercise/
Conversion
Period (xi) | | Physical or
cash
settlement(xii) | | Number of
voting rights | | % of voting rights | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | SUBTOTAL 8.B.2 | | | | | |
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “x”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer(xiii) | o |
| |
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary) | o |
Name(xv) | | % of voting rights if it
equals or is higher
than the notifiable
threshold | | % of voting rights
through financial
instruments if it equals
or is higher than the
notifiable threshold | | Total of both if it
equals or is higher
than the notifiable
threshold |
| | | | | | |
| | | | | | |
| | | | | | |
10. In case of proxy voting, please identify:
Name of the proxy holder | |
| |
The number and % of voting rights held | |
| |
The date until which the voting rights will be held | |
11. Additional information(xvi)
Place of completion | |
| |
Date of completion | September 22 2017 |
